title: Intraoperative brainstem auditory evoked potential pattern and perioperative vasoactive treatment for hearing preservation in vestibular schwannoma surgery.
abstract: OBJECTIVE
  In vestibular schwannoma surgery, four different intraoperative brainstem auditory evoked potential (BAEP) patterns (stable BAEP, abrupt loss, irreversible progressive loss, reversible loss) can be identified and correlated with postoperative hearing outcome. Patients with reversible loss significantly benefit from postoperative vasoactive treatment consisting of hydroxyethyl starch and nimodipine. The present study investigates the treatment effect in the remaining three BAEP patterns.
  
  
  METHODS
  A retrospective analysis was performed in 92 patients operated on for vestibular schwannoma between 1997 and 2005. Between 1997 and 2001, only patients with reversible loss of BAEP received vasoactive medication. Subsequently, all patients operated on between 2001 and 2005 received a 10 day course of therapy, regardless of the BAEP pattern. Serial audiological examinations before, after surgery and after 1 year were performed in all patients.
  
  
  RESULTS
  All 30 patients with reversible loss of BAEP received medication, and postoperative hearing preservation was documented in 21 patients. All 13 patients with stable waves showed hearing preservation, regardless of treatment. In all 24 patients with abrupt loss and in all 25 patients with irreversible progressive loss, postoperative anacusis was documented, regardless of treatment.
  
  
  CONCLUSIONS
  In patients with reversible loss of BAEP, a disturbed microcirculation of the cochlear nerve seems to be the underlying pathophysiological factor. In patients with abrupt or irreversible progressive loss, additional mechanical injury of nerve fibres determines hearing outcome. The study provides evidence that for the purpose of hearing preservation, only patients with reversible loss of BAEP benefit from vasoactive treatment.
authors.affiliation: Department of Neurosurgery, University of Erlangen-Nuremberg, Erlangen, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Bischoff
authors.forename: J
authors.initials: J
authors.lastname: Romstöck
authors.forename: R
authors.initials: R
authors.lastname: Fahlbusch
authors.forename: M
authors.initials: M
authors.lastname: Buchfelder
authors.forename: C
authors.initials: C
authors.lastname: Strauss
mesh_terms: D000328:Adult; D001933:Brain Stem / Q000503:physiopathology; D003056:Cochlear Nerve / Q000098:blood supply / Q000293:injuries; D003638:Deafness / Q000188:drug therapy / Q000503:physiopathology; D016057:Evoked Potentials, Auditory, Brain Stem / Q000502:physiology*; D005260:Female; D005500:Follow-Up Studies; D006309:Hearing / Q000502:physiology*; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000627:therapeutic use; D007511:Ischemia / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008833:Microcirculation / Q000503:physiopathology; D008875:Middle Aged; D016343:Monitoring, Intraoperative; D009464:Neuroma, Acoustic / Q000503:physiopathology / Q000601:surgery*; D009553:Nimodipine / Q000627:therapeutic use; D011183:Postoperative Complications / Q000188:drug therapy / Q000503:physiopathology; D012189:Retrospective Studies; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D006895:Hydroxyethyl Starch Derivatives; D014665:Vasodilator Agents; D009553:Nimodipine